Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), recently executed a series of stock transactions ...

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stock has reached a new 52-week high, touching $39.38 as the company continues to show robust performance in the pharmaceutical sector. According to ...

View Supernus Pharmaceuticals, Inc. (SUPN) current and estimated P/E ratio data provided by Seeking Alpha.

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to ...

In a report released yesterday, Andrew Tsai from Jefferies reiterated a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report), with a price target of $40.00. The company’s shares ...

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in ...

The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...

Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We’re thrilled to see the impact that Qelbree has had on people living with ADHD, including Jay Glazer, and ...

Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), recently executed a series of stock transactions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ITCI Intra-Cellular Therapies, Inc.